Suppression of CD300A inhibits the growth of diffuse large B-cell lymphoma

Lei Jiang; Yulian Xu; Xinli Zeng; Jianchen Fang; Herbert C. Morse III; Jeff X. Zhou

doi:10.18632/oncotarget.5152

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

This article has been corrected. Correction in: Oncotarget. 2017; 8:32380.

Suppression of CD300A inhibits the growth of diffuse large B-cell lymphoma

Lei Jiang, Yulian Xu, Xinli Zeng, Jianchen Fang, Herbert C. Morse III and Jeff X. Zhou _

PDF | HTML | How to cite

Oncotarget. 2015; 6:31191-31202. https://doi.org/10.18632/oncotarget.5152

Metrics: PDF 2266 views | HTML 2181 views | ?

Abstract

Lei Jiang1, Yulian Xu1, Xinli Zeng2, Jianchen Fang3, Herbert C. Morse III4, Jeff X. Zhou1

1Department of Pathology, Zhejiang Provincial Key Laboratory of Pathophysiology, Ningbo University School of Medicine, Ningbo, China

2Department of ENT, Ningbo Second People's Hospital, Ningbo, China

3Ningbo Pathology Service Center, Ningbo, China

4Laboratory of Immunopathology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA

Correspondence to:

Jeff X. Zhou, e-mail: [email protected]

Keywords: diffuse large B-cell lymphoma, CD300A, PI3K/AKT, lymphomagenesis

Received: February 23, 2015 Accepted: August 20, 2015 Published: September 02, 2015

ABSTRACT

CD300A is a type I transmembrane receptor protein which has shown inhibitory effects on B-cell receptor-mediated signals. In an analysis of public dataset, we found that CD300A mRNA levels were inversely correlated with the overall survival time of patients with diffuse large B-cell lymphoma (DLBCL). To decipher the role of CD300A in DLBCL, we knocked down the expression levels of CD300A in DLBCL cells and found that decreasing levels of CD300A significantly inhibited cell proliferation of OCI-Ly01, Farage, and SUDHL-4 cells, but not of VAL, OCI-Ly10, or SUDHL-8 cells. Mechanistically, reduced expression of CD300A resulted in a marked attenuation of AKT phosphorylation, a key molecular event in tumorigenesis, in OCI-Ly01, Farage, and SUDHL-4 cells. Pharmacologic inhibition of PI3K displayed a similar inhibitory effect on cell proliferation. Furthermore, using a xenograft animal model, we found that decreasing levels of CD300A in OCI-Ly01 and Farage cells significantly inhibited tumor formation in vivo. Collectively, our results suggested an oncogenic role of CD300A in DLBCL which could serve as a potential biomarker and therapeutic target for this malignant disease.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5152

Publication Alerts

Research Papers:

Suppression of CD300A inhibits the growth of diffuse large B-cell lymphoma

Abstract